share_log

Pfizer | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Pfizer Inc. (“Pfizer” or the “Reporting Person”)(32.0%)

Pfizer | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

輝瑞 | SC 13D/A：超過5%持股股東披露文件(修正)
SEC announcement ·  03/20 08:53
牛牛AI助理已提取核心訊息
On March 19, 2024, Pfizer Inc. (Pfizer), a leading pharmaceutical company, filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission (SEC), detailing its ownership stake in Haleon plc. Pfizer reported beneficial ownership of approximately 32% of Haleon's outstanding Ordinary Shares, amounting to 2,955,063,626 shares. This ownership includes both restricted American Depositary Shares (ADSs) and Ordinary Shares held by Pfizer's nominee. The filing was an update to a series of amendments dating back to July 27, 2022, and reflects Pfizer's position prior to a secondary offering and share buyback planned for March 2024. The secondary offering involves the sale of 790,554,820 Ordinary Shares, including both Ordinary Shares and Unrestricted ADSs, with Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, and other underwriters facilitating the transaction. Pfizer has entered into a lock-up agreement restricting the sale of additional shares for 90 days post-offering. The secondary offering and share buyback are expected to close on March 21, 2024, subject to customary conditions.
On March 19, 2024, Pfizer Inc. (Pfizer), a leading pharmaceutical company, filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission (SEC), detailing its ownership stake in Haleon plc. Pfizer reported beneficial ownership of approximately 32% of Haleon's outstanding Ordinary Shares, amounting to 2,955,063,626 shares. This ownership includes both restricted American Depositary Shares (ADSs) and Ordinary Shares held by Pfizer's nominee. The filing was an update to a series of amendments dating back to July 27, 2022, and reflects Pfizer's position prior to a secondary offering and share buyback planned for March 2024. The secondary offering involves the sale of 790,554,820 Ordinary Shares, including both Ordinary Shares and Unrestricted ADSs, with Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, and other underwriters facilitating the transaction. Pfizer has entered into a lock-up agreement restricting the sale of additional shares for 90 days post-offering. The secondary offering and share buyback are expected to close on March 21, 2024, subject to customary conditions.
2024年3月19日，領先的製藥公司輝瑞公司（Pfizer）向美國證券交易委員會（SEC）提交了附表13D的修正案，詳細說明了其在Haleon plc的所有權。輝瑞報告稱，Haleon已發行普通股約32％的受益所有權，共計2,955,063,626股。該所有權包括輝瑞提名人持有的限制性美國存托股票（ADS）和普通股。該文件是對可追溯到2022年7月27日的一系列修正案的更新，反映了輝瑞在計劃於2024年3月進行二次發行和股票回購之前的立場。二次發行涉及向花旗集團環球市場公司、摩根士丹利公司出售790,554,820股普通股，包括普通股和非限制性存託憑證。有限責任公司和其他爲交易提供便利的承銷商。輝瑞已簽訂封鎖協議，限制在發行後的90天內出售額外股票。根據慣例條件，二次發行和股票回購預計將於2024年3月21日結束。
2024年3月19日，領先的製藥公司輝瑞公司（Pfizer）向美國證券交易委員會（SEC）提交了附表13D的修正案，詳細說明了其在Haleon plc的所有權。輝瑞報告稱，Haleon已發行普通股約32％的受益所有權，共計2,955,063,626股。該所有權包括輝瑞提名人持有的限制性美國存托股票（ADS）和普通股。該文件是對可追溯到2022年7月27日的一系列修正案的更新，反映了輝瑞在計劃於2024年3月進行二次發行和股票回購之前的立場。二次發行涉及向花旗集團環球市場公司、摩根士丹利公司出售790,554,820股普通股，包括普通股和非限制性存託憑證。有限責任公司和其他爲交易提供便利的承銷商。輝瑞已簽訂封鎖協議，限制在發行後的90天內出售額外股票。根據慣例條件，二次發行和股票回購預計將於2024年3月21日結束。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。